1st Quarter - Report
BECTON, DICKINSON AND COMPANY for BECTON DICKINSON AND COMPANY
Client
Income
—
Expenses
$450,000
Expense method
C: businesses, Internal Revenue Code section 162(e)
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R.184, Protect Medical Innovation Act of 2017 H.R.1, Tax Cuts and Jobs Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| JESSICA JOHNSTON | — |
| DANNY LY | — |
| TODD SPANGLER | — |
| ELIZABETH WOODY | — |
Budget/Appropriations BUD
NIH funding Global health funding CDC funding
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANNY LY | — |
Health Issues HCR
Issues related to antimicrobial resistance H.R.2430, FDA Reauthorization Act of 2017 VA procurement Issues related to hazardous drug safety Issues related to medical technology regulation P.L.109-417 PAHPA Opioids
| Lobbyist | Covered position, as disclosed |
|---|---|
| JESSICA JOHNSTON | — |
| DANNY LY | — |
| TODD SPANGLER | — |
| ELIZABETH WOODY | — |
Medical/Disease Research/Clinical Labs MED
Issues related to device cybersecurity
| Lobbyist | Covered position, as disclosed |
|---|---|
| TODD SPANGLER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.